CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.10% for the 12-month period ending 2025-12-27, per its 10-K filed 2026-02-18.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-02-18
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2013-03-30 was 0.81%, a 3.57% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2012-03-31 was 0.84%, a 62.33% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2011-03-26 was 2.23%.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.10%, a 6.82% decline from fiscal 2024.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.40%, a 15.79% increase from fiscal 2023.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.80%, a 40.74% increase from fiscal 2022.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.70%, a 170.00% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-27 | 4.10% 10-K · filed 2026-02-18 | ||||
| 2024-12-28 | 4.40% 10-K · filed 2026-02-18 | ||||
| 2023-12-30 | 3.80% 10-K · filed 2026-02-18 | ||||
| 2022-12-31 | 2.70% 10-K · filed 2025-02-19 | ||||
| 2021-12-25 | 1.00% 10-K · filed 2024-02-14 | ||||
| 2020-12-26 | 0.40% 10-K · filed 2023-02-22 | ||||
| 2019-12-28 | 2.40% 10-K · filed 2022-02-16 | ||||
| 2018-12-29 | 2.40% 10-K · filed 2021-02-17 | ||||
| 2017-12-30 | 1.60% 10-K · filed 2020-02-11 | ||||
| 2016-12-31 | 1.20% 10-K · filed 2019-02-13 | ||||
| 2015-12-26 | 1.10% 10-K · filed 2018-02-13 | ||||
| 2014-12-27 | 1.50% 10-K · filed 2017-02-14 | 1.55% 10-K · filed 2015-02-17 | |||
| 2013-12-28 | 0.80% 10-K · filed 2016-02-12 | ||||
| 2013-09-28 | 0.80% 10-Q · filed 2013-10-30 | ||||
| 2013-06-29 | 0.80% 10-Q · filed 2013-07-31 | ||||
| 2013-03-30 | 0.81% 10-Q · filed 2013-05-08 | ||||
| 2012-12-29 | 0.84% 10-K · filed 2015-02-17 | ||||
| 2012-09-29 | 0.84% 10-Q · filed 2013-10-30 | ||||
| 2012-06-30 | 0.84% 10-Q · filed 2013-07-31 | ||||
| 2012-03-31 | 0.84% 10-Q · filed 2013-05-08 | ||||
| 2011-12-31 | 2.21% 10-K · filed 2014-02-25 | ||||
| 2011-09-24 | 2.22% 10-Q · filed 2012-11-01 | ||||
| 2011-06-25 | 2.22% 10-Q · filed 2012-08-07 | ||||
| 2011-03-26 | 2.23% 10-Q · filed 2012-05-04 | ||||
| 2010-12-25 | 2.35% 10-K · filed 2013-02-27 | ||||
| 2010-09-25 | 2.35% 10-Q · filed 2011-11-02 | ||||
| 2010-06-26 | 2.35% 10-Q · filed 2011-08-03 | ||||
| 2009-12-26 | 1.87% 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |